ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 855,20
1,08%
Dow Jones
44 156,73
0,30%
DAX
21 254,27
1,01%
Brent Oil
78,135
-0,26%
Bitcoin
102 402,88
-1,19%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Kronos Bio Inc (KRON)

  7. Kronos Bio Inc (KRON) Actualités

KRON

Kronos Bio (KRON)

Kronos Bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KRON
DateHeureSourceTitreSymboleSociété
27/11/202415h25AllPennyStocks.comCalifornia Biotech Stock Bid Up Prior To Opening Bell On Major AnnouncementNASDAQ:KRONKronos Bio Inc
27/11/202413h30GlobeNewswire Inc.Kronos Bio Announces CEO Transition and Reduction in ForceNASDAQ:KRONKronos Bio Inc
15/11/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KRONKronos Bio Inc
14/11/202422h02GlobeNewswire Inc.Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024NASDAQ:KRONKronos Bio Inc
13/11/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
13/11/202422h05GlobeNewswire Inc.Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic AlternativesNASDAQ:KRONKronos Bio Inc
07/11/202422h47Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KRONKronos Bio Inc
05/11/202415h00GlobeNewswire Inc.Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple MyelomaNASDAQ:KRONKronos Bio Inc
23/10/202414h55GlobeNewswire Inc.Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven TumorsNASDAQ:KRONKronos Bio Inc
16/10/202400h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
09/10/202414h55GlobeNewswire Inc.Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven TumorsNASDAQ:KRONKronos Bio Inc
07/10/202414h55GlobeNewswire Inc.Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s DiseaseNASDAQ:KRONKronos Bio Inc
25/09/202414h55GlobeNewswire Inc.Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory TherapyNASDAQ:KRONKronos Bio Inc
23/09/202414h55GlobeNewswire Inc.Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian CancerNASDAQ:KRONKronos Bio Inc
03/09/202414h55GlobeNewswire Inc.Kronos Bio Announces Participation in Medical and Investor Conferences in SeptemberNASDAQ:KRONKronos Bio Inc
08/08/202422h15GlobeNewswire Inc.Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline UpdateNASDAQ:KRONKronos Bio Inc
08/08/202422h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
23/07/202422h15GlobeNewswire Inc.Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian CancerNASDAQ:KRONKronos Bio Inc
04/06/202422h58Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
23/05/202423h15GlobeNewswire Inc.Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:KRONKronos Bio Inc
22/05/202422h30GlobeNewswire Inc.Kronos Bio to Participate in Three Upcoming Healthcare Conferences and EventsNASDAQ:KRONKronos Bio Inc
21/05/202422h15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRONKronos Bio Inc
21/05/202414h15GlobeNewswire Inc.Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer NASDAQ:KRONKronos Bio Inc
09/05/202422h05GlobeNewswire Inc.Kronos Bio Reports First-Quarter 2024 Financial ResultsNASDAQ:KRONKronos Bio Inc
21/03/202412h05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
07/03/202422h05GlobeNewswire Inc.Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash RunwayNASDAQ:KRONKronos Bio Inc
05/03/202422h44GlobeNewswire Inc.Kronos Bio To Present Three Posters at AACR 2024 Annual MeetingNASDAQ:KRONKronos Bio Inc
27/02/202422h05GlobeNewswire Inc.Kronos Bio Announces Participation in 44th Annual Cowen Health Care ConferenceNASDAQ:KRONKronos Bio Inc
18/12/202322h06GlobeNewswire Inc.Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development CandidateNASDAQ:KRONKronos Bio Inc
04/12/202314h00GlobeNewswire Inc.Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:KRONKronos Bio Inc
 Showing the most relevant articles for your search:NASDAQ:KRON

Dernières Valeurs Consultées

EU
MC
Lvmh Moet Hennessy Louis...
EU
SGO
Cie de SaintGobain
EU
AI
Air Liquide
USI
USTECH100
US Tech 100
NYSE
NKE
Nike
EU
RNO
Renault
EU
DG
Vinci
COIN
DOGEUSD
Dogecoin
EU
RI
Pernod Ricard
EU
HO
Thales
EU
ML
Michelin
NYSE
MRK
Merck
COIN
ETHUSD
Ethereum
EU
BNP
BNP Paribas
EU
ACA
Credit Agricole
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés